Effect of statins on β-amyloid metabolism in humans: Potential importance for the development of senile plaques in Alzheimer's disease

Acta Neurologica Scandinavica

Volumn 114, Issue SUPPL. 185, 2006, Pages 87-92

  Hoglund K ^a,b   Wallin, A ^a   Blennow, K ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Institute of Clinical Neuroscience   (Sweden)

Author keywords

amyloid; Alzheimer's disease; Amyloid precursor protein; Cerebrospinal fluid; Cholesterol; Plasma; Statins

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; SIMVASTATIN; TRIACYLGLYCEROL; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPERCHOLESTEROLEMIA; MINI MENTAL STATE EXAMINATION; NEUROLOGIC DISEASE; REVIEW; SENILE PLAQUE; TREATMENT OUTCOME; BRAIN; DRUG EFFECT; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BRAIN; CHOLESTEROL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SENILE PLAQUES;

EID: 33745740860     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2006.00691.x     Document Type: Review

References (46)

1. BODOVITZ S, KLEIN WL. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 1996;271:4436-40.
2. FASSBENDER K, SIMONS M, BERGMANN C et al. Simvastatin strongly reduces levels of Alzheimer's disease beta - amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A 2001;98:5856-61.
3. FREARS ER, STEPHENS DJ, WALTERS CE, DAVIES H, AUSTEN BM. The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport 1999;10:1699-705.
4. SIMONS M, KELLER P, DE STROOPER B, BEYREUTHER K, DOTTI CG, SIMONS K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 1998;95:6460-4.
5. SPARKS DL, SCHEFF SW, HUNSAKER JC III, LIU H, LANDERS T, GROSS DR. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 1994;126:88-94.
6. KIVIPELTO M, HELKALA EL, HANNINEN T et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 2001;56:1683-9.
7. KIVIPELTO M, HELKALA EL, LAAKSO MP et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001;322:1447-51.
8. NOTKOLA IL, SULKAVA R, PEKKANEN J et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998;17:14-20.
9. JICK H, ZORNBERG GL, JICK SS, SESHADRI S, DRACHMAN DA. Statins and the risk of dementia. Lancet 2000;356:1627-31.
10. ROCKWOOD K, KIRKLAND S, HOGAN DB et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002;59:223-7.
11. WOLOZIN B, KELLMAN W, RUOSSEAU P, CELESIA GG, SIEGEL G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-43.
12. SIMONS M, SCHWARZLER F, LÜTJOHANN D et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002;52:346-50.
13. FRIEDHOFF LT, CULLEN EI, GEOGHAGEN NS, BUXBAUM JD. Treatment with controlled- release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. Int J Neuropsychopharmacol 2001;4:127-30.
14. CORDER EH, SAUNDERS AM, STRITTMATTER WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-3.
15. SAUNDERS AM, STRITTMATTER WJ, SCHMECHEL D et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-72.
16. POIRIER J. Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Ann N Y Acad Sci 2000;924:81-90.
17. GIUBILEI F, D'ANTONA R, ANTONINI R, LENZI GL, RICCI G, FIESCHI C. Serum lipoprotein pattern variations in dementia and ischemic stroke. Acta Neurol Scand 1990;81:84-6.
18. JARVIK GP, WIJSMAN EM, KUKULL WA, SCHELLENBERG GD, YU C, LARSON EB. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 1995;45:1092-6.
19. BERTRAND P, POIRIER J, ODA T, FINCH CE, PASINETTI GM. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res Mol Brain Res 1995;33:174-8.
20. BLENNOW K, HESSE C, FREDMAN P. Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease. Neuroreport 1994;5:2534-6.
21. WEHR H, PARNOWSKI T, PUZYNSKI S et al. Apolipoprotein E genotype and lipid and lipoprotein levels in dementia. Dement Geriatr Cogn Disord 2000;11:70-3.
22. Heart. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
23. SHEPHERD J, BLAUW GJ, MURPHY MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
24. ZANDI PP, SPARKS DL, KHACHATURIAN AS et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 2005;62:217-24.
25. PARK IH, HWANG EM, HONG HS et al. Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. Neurobiol Aging 2003;24:637-43.
26. FASSBENDER K, STROICK M, BERTSCH T et al. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 2002;59:1257-8.
27. ISHII K, TOKUDA T, MATSUSHIMA T et al. Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid-beta (Abeta) 40 or Abeta 42 in humans. Neurosci Lett 2003;350:161-4.
28. TOKUDA T, TAMAOKA A, MATSUNO S et al. Plasma levels of amyloid beta proteins did not differ between subjects taking statins and those not taking statins. Ann Neurol 2001;49:546-7.
29. ENGELHART MJ, GEERLINGS MI, RUITENBERG A et al. Diet and risk of dementia: does fat matter? The Rotterdam Study. Neurology 2002;59:1915-21.
30. KALMIJN S, LAUNER LJ, OTT A, WITTEMAN JC, HOFMAN A, BRETELER MM. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 1997;42:776-82.
31. BLENNOW K, HAMPEL H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-13.
32. BJÖRKHEM I, LÜTJOHANN D, DICZFALUSY U, STAHLE L, AHLBORG G, WAHREN J. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res 1998;39:1594-600.
33. SJÖGREN M, GUSTAFSSON K, SYVERSEN S et al. Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein. Dement Geriatr Cogn Disord 2003;16:25-30.
34. HÖGLUND K, WIKLUND O, VANDERSTICHELE H, EIKENBERG O, VANMECHELEN E, BLENNOW K. Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurol 2004;61:333-7.
35. HÖGLUND K, THELEN KM, SYVERSEN S et al. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2005;19:256-65.
36. KOBAYASHI J, MARUYAMA T, MASUDA M, SHINOMIYA M. Effect of atorvastatin treatment on lipoprotein lipase mass in the pre-heparin plasma in Japanese hyperlipidemic subjects. Clin Chim Acta 2001;314:261-4.
37. LOCATELLI S, LUTJOHANN D, SCHMIDT HH, OTTO C, BEISIEGEL U, VON BERGMANN K. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol 2002;59:213-6.
38. PAPASSOTIROPOULOS A, LÜTJOHANN D, BAGLI M et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res 2002;36:27-32.
39. SCHONKNECHT P, LÜTJOHANN D, PANTEL J et al. Cerebrospinal fluid 24S- hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neurosci Lett 2002;324:83-5.
40. LÜTJOHANN D, BREUER O, AHLBORG G et al. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci U S A 1996;93:9799-804.
41. OHM TG, TREIBER-HELD S, DISTL R et al. Cholesterol and tau protein-findings in Alzheimer's and Niemann Pick C's disease. Pharmacopsychiatry 2003;36(Suppl. 2):S120-6.
42. HÖGLUND K, SYVERSEN S, LEWCZUK P, WALLIN A, WILTFANG J, BLENNOW K. Statin treatment and a disease specific pattern of Aβ peptides in Alzheimer's disease. Exp Brain Res 2005;164(2):205-14.
43. WILTFANG J, ESSELMANN H, BIBL M et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem 2002;81:481-96.
44. VAUGHAN CJ, MURPHY MB, BUCKLEY BM. Statins do more than just lower cholesterol. Lancet 1996;348:1079-82.
45. LAUFS U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol 2003;58:719-31.
46. DELANTY N, VAUGHAN CJ, SHEEHY N. Statins and neuroprotection. Expert Opin Investig Drugs 2001;10:1847-53.